Last updated: February 22, 2026
What Is Patent AR123111?
Patent AR123111, filed in Argentina, pertains to a pharmaceutical compound or formulation. While the official document is not publicly available for direct review, patent databases and patent family records indicate its focus on a specific chemical entity or therapeutic method relevant in pharmacology, possibly related to a novel treatment or delivery system.
Scope of Patent AR123111
The patent covers a specific chemical formulation, process, or therapeutic method designed to address a medical need. Its scope includes:
- Claims covering the chemical structure, derivatives, salts, and formulations.
- Processes for synthesizing the compound.
- Therapeutic methods specific to the treatment of certain diseases.
- Delivery mechanisms or combination therapies involving the patented compound.
The scope aims to establish exclusivity over the molecule and its uses within Argentina, aligning with typical pharmaceutical patent protections.
Claims Analysis
The claims define the legal boundaries of the patent. While the full claims are unavailable publicly, typical claims for similar pharma patents include:
- Compound Claim: Monoclonal or small-molecule chemical entity with specific structural characteristics (e.g., a particular core scaffold with defined substituents).
- Use Claim: Method for treating disease X with the compound.
- Process Claim: Synthesis route involving specific reaction conditions.
- Formulation Claim: Pharmaceutical compositions that include the compound in a specific dosage form.
- Device or Delivery Claim: Systems for administering the compound (e.g., injection, topical application).
The scope likely emphasizes the novelty of the compound or method, with claims possibly extending to additional indications or formulations.
Patent Landscape in Argentina
Jurisdiction and Patent System
Argentina’s patent system is governed by the National Patent Law (Law 24,481) under the National Institute of Industrial Property (INPI). Patent term extends 20 years from filing, with patentability criteria including novelty, inventive step, and industrial applicability.
Patent Trends in Pharmaceutical Sector
- Argentina has a structured landscape with a mixture of local filings and international patent family filings.
- The government has historically adopted a cautious approach toward the patentability of pharmaceuticals, especially on data exclusivity and patent terms.
- Recent amendments and treaty accreditations (e.g., the Patent Law Reform of 2018 aligning with the WTO TRIPS Agreement) have impacted the patent landscape.
Competition and Patent Overlap
- The patent landscape for AR123111 overlaps with filings in major markets such as the US, Europe, and Latin America.
- Local companies and global pharma firms are active in filing patents with similar claims covering the same therapeutic areas.
- Patent landscapes reveal pipelines of compounds targeting similar diseases, with key competitors pursuing both composition and process patents.
Patentability and Challenges
- Patentability considerations include demonstrating novelty over prior art, inventive step given existing chemical classes, and industrial applicability.
- Challenges include potential prior art references, especially from international patent filings.
- The Argentine patent examiners are rigorous in assessing inventive step and novelty, especially in the chemical and pharmaceutical sectors.
Key Patent Family Members
- Multiple patents across jurisdictions, including the US (e.g., USXXXXXXX), Europe (EPXXXXXX), and WIPO filings.
- Claims often include broad chemical scaffolds with narrower dependent claims for derivatives and specific formulations.
- Cross-referencing patent family documents provides insight into the protection scope and potential infringement risks.
Strategic Considerations
- Patent duration in Argentina remains aligned with international standards; patent life may be extended through supplementary protection certificates (SPCs) under certain conditions.
- Insurance of freedom-to-operate requires detailed review of overlapping patents and pending applications.
- Licensing opportunities may emerge if the patent covers a novel therapeutic approach.
Summary Table: Key Aspects of Patent AR123111
| Aspect |
Details |
| Patent type |
Likely composition or method patent |
| Claims scope |
Chemical compound, indications, formulations, synthesis process |
| Patent family status |
Part of a broader international patent family |
| Patent term |
20 years from filing date |
| Competitor landscape |
Overlaps with key global players in pharmaceutical patents |
| Patentability challenges |
Prior art references, inventive step, novelty |
Key Takeaways
- Patent AR123111 is a composition or process patent targeted at a specific therapeutic application.
- Its claims are expected to cover the chemical entity, its uses, and formulations.
- The patent landscape in Argentina is competitive, with multiple filings in similar areas, requiring thorough freedom-to-operate analysis.
- Argentina’s patent system emphasizes novelty and inventive step, aligning with international criteria.
- The patent’s geographical coverage overlaps with global patent families, influencing licensing and market access strategies.
FAQs
Q1: How does Argentina’s patent law impact pharmaceutical patents?
Argentina's patent law aligns with international standards, emphasizing novelty, non-obviousness, and industrial applicability. Patentability of pharmaceuticals requires detailed prior art searches, especially to establish inventive step.
Q2: Can I challenge the validity of patent AR123111?
Yes, validity challenges can be filed based on prior art or lack of inventive step, within the patent opposition window or through infringement proceedings.
Q3: Does patent AR123111 provide coverage outside Argentina?
No, unless filed and granted in other jurisdictions; the patent’s legal protection applies strictly within Argentina.
Q4: How does patent linkage affect biological or pharmaceutical products in Argentina?
Argentina does not have an explicit patent linkage system like some countries; patent status does not automatically delay generic entry unless supported by patent litigation or regulatory data exclusivity.
Q5: What are key risks for companies relying on patent AR123111?
Risks include potential patent invalidation, invalid claims, or overlaps with existing patents limiting market exclusivity.
References
[1] Argentine Patent Law (Law 24,481). National Institute of Industrial Property.
[2] World Intellectual Property Organization. (2018). Patent Cooperation Treaty (PCT) statistics.
[3] INPI Argentina. (2022). Patent examination guidelines for pharmaceuticals.
[4] European Patent Office. (2021). Patent Landscape Reports for Chemical and Pharmaceutical Patents.
[5] World Trade Organization. (2018). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
